Norbert Pardi
Impact in
- Infectious Diseases top 0.2%
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Immunology top 0.5%
- Immunotherapy and Immune Responses
Papers in
-
- RNA Interference and Gene Delivery 34
-
- SARS-CoV-2 and COVID-19 Research 23
- Viral gastroenteritis research and epidemiology 11
- Co-authors
- Drew Weissman (48 shared papers)Michael J. Hogan (8 shared papers)Frederick Porter (1 shared paper)Hiromi Muramatsu (37 shared papers)Ying K. Tam (31 shared papers)Katalin Karikó (11 shared papers)Barbara L. Mui (9 shared papers)Thomas D. Madden (7 shared papers)
- Journals
- Nature Communications (7 papers)Vaccine (5 papers)Molecular Therapy (5 papers)npj Vaccines (4 papers)Journal of Controlled Release (3 papers)
- Partner nations
- United StatesHungaryGermany
In The Last Decade
Norbert Pardi
78 papers receiving 9.1k citations
Norbert Pardi's Hit Papers
Peers
Comparison fields: 5 of 139
- Infectious Diseases 3.1k
- Immunology 2.5k
- Molecular Biology 5.3k
- Animal Science and Zoology 757
- Virology 246
Countries citing papers authored by Norbert Pardi
This map shows the geographic impact of Norbert Pardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Pardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Pardi more than expected).
Fields of papers citing papers by Norbert Pardi
This network shows the impact of papers produced by Norbert Pardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Pardi. The network helps show where Norbert Pardi may publish in the future.
Co-authors
The 25 scholars most cited alongside Norbert Pardi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | mRNA vaccines — a new era in vaccinology Hit paper breakdown → | 2018 | 3197 |
| 2 | Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes Hit paper breakdown → | 2015 | 723 |
| 3 | Recent advances in mRNA vaccine technology Hit paper breakdown → | 2020 | 360 |
| 4 | Innate immune mechanisms of mRNA vaccines Hit paper breakdown → | 2022 | 284 |
| 5 | Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge Hit paper breakdown → | 2017 | 279 |
| 6 | SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation Hit paper breakdown → | 2020 | 239 |
| 7 | A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes Hit paper breakdown → | 2022 | 237 |
| 8 | Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine Hit paper breakdown → | 2022 | 224 |
| 9 | Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs Hit paper breakdown → | 2021 | 221 |
| 10 | A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice Hit paper breakdown → | 2020 | 216 |
| 11 | Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies Hit paper breakdown → | 2018 | 207 |
| 12 | PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake Hit paper breakdown → | 2018 | 172 |
| 13 | 2021 | 166 | |
| 14 | Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer Hit paper breakdown → | 2023 | 151 |
| 15 | 2012 | 139 | |
| 16 | 2012 | 138 | |
| 17 | Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability Hit paper breakdown → | 2023 | 128 |
| 18 | Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA Hit paper breakdown → | 2021 | 113 |
| 19 | 2018 | 106 | |
| 20 | mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent Hit paper breakdown → | 2021 | 106 |
About Norbert Pardi
Norbert Pardi is a scholar working on Molecular Biology, Infectious Diseases, Immunology, Epidemiology and Genetics, having authored 85 papers that have together received 9.3k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (34 papers), SARS-CoV-2 and COVID-19 Research (23 papers), Immunotherapy and Immune Responses (17 papers), Animal Virus Infections Studies (14 papers), Virus-based gene therapy research (14 papers), Viral gastroenteritis research and epidemiology (11 papers), Influenza Virus Research Studies (9 papers) and Herpesvirus Infections and Treatments (6 papers). The work is most often cited by research in Infectious Diseases (3.1k citations), Immunology (2.5k citations), Molecular Biology (5.3k citations), Animal Science and Zoology (757 citations) and Virology (246 citations). Norbert Pardi has collaborated with scholars based in United States, Hungary and Germany. Frequent co-authors include Drew Weissman, Michael J. Hogan, Frederick Porter, Hiromi Muramatsu, Ying K. Tam, Katalin Karikó, Barbara L. Mui, Thomas D. Madden, Michael J. Hope and Florian Krammer. Their work appears in journals such as Nature Communications, Vaccine, Molecular Therapy, npj Vaccines and Journal of Controlled Release.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.